<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pill esophagitis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pill esophagitis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pill esophagitis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Kahrilas, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">J Thomas Lamont, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 04, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Medications can induce esophageal abnormalities via both causing direct esophageal mucosal injury and by systemic effects. Potential systemic effects include gastroesophageal reflux and medication-induced infectious complications.</p><p>This topic will review medication-induced esophagitis from direct esophageal mucosal injury, also known as pill esophagitis. The pathophysiology of reflux esophagitis and the clinical manifestations, diagnosis, and management of other causes of esophagitis are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2257.html" rel="external">"Pathophysiology of reflux esophagitis"</a> and  <a class="medical medical_review" href="/z/d/html/2243.html" rel="external">"Clinical manifestations and diagnosis of eosinophilic esophagitis (EoE)"</a> and  <a class="medical medical_review" href="/z/d/html/2241.html" rel="external">"Approach to the evaluation of dysphagia in adults"</a>.)</p><p class="headingAnchor" id="H174813199"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Most medication-induced esophagitis is unreported and/or undetected, and only severe cases seek medical attention, making it difficult to accurately determine the incidence or prevalence [<a href="#rid1">1</a>]. Overall, the mean age at diagnosis is 41.5 years with a slightly higher prevalence in females, which is likely to be reflective of the population using culprit medications rather than a sex- or age-related increase in susceptibility [<a href="#rid1">1,2</a>]. Pill esophagitis usually occurs in the mid esophagus [<a href="#rid3">3</a>]. This corresponds to areas of extrinsic compression by the mainstem bronchus, aorta, or cardiac atrium where pills or capsules are likely to lodge when swallowed with inadequate volumes of liquid and/or in a supine posture [<a href="#rid4">4,5</a>].</p><p class="headingAnchor" id="H105736283"><span class="h1">ETIOLOGY</span></p><p class="headingAnchor" id="H2290851249"><span class="h2">Culprit medications</span><span class="headingEndMark"> — </span>More than 100 different medications have been reported to cause pill esophagitis  (<a class="graphic graphic_table graphicRef135178" href="/z/d/graphic/135178.html" rel="external">table 1</a>) [<a href="#rid1">1,6-8</a>]. Frequently prescribed medications associated with pill esophagitis include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotics</strong> – Antibiotics account for approximately 50 percent of reported cases of pill esophagitis and the most frequent etiology of pill esophagitis in younger adults. Tetracyclines are the most common antibiotic class implicated, but penicillins, <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a>, <a class="drug drug_general" data-topicid="10113" href="/z/d/drug information/10113.html" rel="external">lincomycin</a>, <a class="drug drug_general" data-topicid="10092" href="/z/d/drug information/10092.html" rel="external">spiramycin</a>, <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a>, rifampicin, sulfamethoxypyridazine, <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">tinidazole</a>, zalcitabine, <a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">zidovudine</a>, and <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> have all been associated with medication-induced esophagitis [<a href="#rid9">9</a>]. Esophagitis is due to the direct irritant effect of the medications on the mucosa. (See <a class="local">'Pathogenesis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonsteroidal anti-inflammatory drugs (NSAIDs)</strong> – Despite the high prevalence of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and NSAID use, they account for less than 10 percent of all reports of pill esophagitis. However, they account for nearly 50 percent of all hemorrhagic complications attributable to medications. NSAID use, although less likely to cause esophagitis, is much more likely to cause hemorrhage, severe esophagitis, and/or esophageal stricture [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bisphosphonates</strong> – All drugs in the bisphosphonate class potentially have adverse gastrointestinal events, including pill esophagitis. In part, this is because bisphosphonates are poorly absorbed from the gastrointestinal tract, with bioavailability of less than 1 percent after oral administration [<a href="#rid10">10</a>]. Hence the recommendation to be taken after an overnight fast and to avoid eating for 30 to 60 minutes after administration. The limited bioavailability after oral administration has also prompted the development of parenterally administered bisphosphates and research into novel delivery systems. (See  <a class="medical medical_review" href="/z/d/html/104424.html" rel="external">"Risks of bisphosphonate therapy in patients with osteoporosis"</a>.)</p><p></p><p class="bulletIndent1">In the first three years after the marketing of <a class="drug drug_general" data-topicid="9427" href="/z/d/drug information/9427.html" rel="external">alendronate</a> in 1995, 24 esophageal injuries were reported, including many cases of severe esophagitis and stricturing. This made it the most common offender for causing pill esophagitis at the time and led to strict recommendations to take the pills with at least 6 ounces of water and to remain in an upright posture for at least 30 minutes afterward. Subsequently, the frequency of reported cases diminished, and by 1999, postmarketing surveillance identified only 75 cases, which amounted to an incidence of only 0.013 percent among the more than one-half million patients for whom prescriptions for alendronate had been written [<a href="#rid1">1</a>]. Thus, although the drug clearly has the potential to be extremely caustic to the esophageal epithelium, the incidence of pill esophagitis is minimized by cautious pill-taking habits. (See <a class="local">'Precautions to decrease risk'</a> below.)</p><p></p><p class="headingAnchor" id="H259723010"><span class="h2">Risk factors</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medication size and administration</strong> – Patient position, the size of the medication, and the amount of fluid ingested are important determinants of the risk of medication-induced esophagitis. This was illustrated in a study that evaluated esophageal transit of six commonly used barium-impregnated medications in 121 healthy volunteers studied with fluoroscopy while controlling for the volume of liquid swallowed and body position. When the subject was in the supine position when pills were swallowed, esophageal transit delay was much more likely to occur, as was the case when swallowing only 25 mL of water compared with 100 mL. Of 726 test swallows, pill transit was delayed in 157 (22 percent). The location at which the tablets lodged were the pyriform (1 percent), aortic arch (10 percent), carina (12 percent), heart (18 percent), and cardia (58 percent). Of note, 67 percent of instances with delayed transit were asymptomatic [<a href="#rid4">4</a>]. For subjects swallowing pills while in the upright position, the quantity of water was not a significant factor with the smaller pills, but delayed esophageal transit occurred with larger tablets and small quantities of water. Similar findings were reported in a study using 6 mm barium-impregnated bread balls during concurrent fluoroscopy and esophageal manometry [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1">Medication-induced esophagitis is frequently associated with ingestion of medication immediately prior to sleep. This is attributable to multiple risk factors: supine posture, often small volumes of water taken with the pill(s), and the minimal salivation and swallowing that occur during sleep [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Functional and anatomic risk factors</strong> – An esophageal motility disorder or altered anatomy (eg, esophageal stricture) may also be a risk factor for pill esophagitis. This is supported by the observation of a higher incidence of pill esophagitis in patients with left atrial enlargement and following thoracic surgery. However, it is unclear if this observation is due to altered anatomy alone or if these patients are older and are therefore more likely to be taking medications associated with esophagitis. (See <a class="local">'Etiology'</a> above.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>It is hypothesized that pill esophagitis is usually caused by prolonged contact of the medication with the esophageal mucosa owing to delayed esophageal transit [<a href="#rid12">12,13</a>]. This hypothesis is supported by the typical esophageal lesion showing a small, punched-out ulcer in a limited area that was conceivably in contact with a high concentration of medication released from a dissolving pill  (<a class="graphic graphic_diagnosticimage graphicRef134866" href="/z/d/graphic/134866.html" rel="external">image 1</a>). In addition, the site of injury is frequently in areas in which the esophageal lumen is compromised by the aortic arch, the carina, the esophagogastric junction, or an enlarged left atrium. The proposed mechanism of direct injury is an intense inflammatory response triggered by the high local concentration of the medication or its osmolality (eg, <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">potassium chloride</a>).</p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Retrosternal pain and odynophagia are the most common presenting symptoms of pill esophagitis. The onset of symptoms after taking pills has not been absolutely defined but is usually within three days of the culprit ingestion, sometimes as quickly as within a few hours [<a href="#rid14">14</a>]. In some cases, the pain may be so severe that swallowing saliva is difficult. Rarely, patients may have hematemesis, abdominal pain, and weight loss [<a href="#rid15">15,16</a>].</p><p class="headingAnchor" id="H6"><span class="h1">DIAGNOSTIC EVALUATION</span></p><p class="headingAnchor" id="H4208663464"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>Pill esophagitis should be suspected in patients with retrosternal pain or heartburn, odynophagia, or dysphagia and a history of ingestion of medications known to cause esophageal injury. Patients often also report swallowing a pill without water, commonly at bedtime. In such cases, a clinical diagnosis may be made by history alone.</p><p>An upper endoscopy should be performed in patients with severe symptoms, atypical symptoms (hematemesis, abdominal pain, and weight loss), or symptoms that persist for <strong>one week </strong>after discontinuation of the culprit medication. In such cases, an upper endoscopy with biopsy serves to establish the diagnosis and to rule out other etiologies. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H174813352"><span class="h2">Upper endoscopy and biopsy in selected patients</span><span class="headingEndMark"> — </span>The most common sites of pill-induced esophageal injury are the proximal esophagus near the compression from the aortic arch or carina and the distal esophagus in patients with left atrial enlargement. The typical endoscopic appearance of pill-induced esophageal injury is of discrete ulceration or kissing ulcers in the mid esophagus with relatively normal surrounding mucosa  (<a class="graphic graphic_diagnosticimage graphicRef134866" href="/z/d/graphic/134866.html" rel="external">image 1</a>) [<a href="#rid3">3</a>]. Ulcers may range in size from 1 or 2 mm to several centimeters. Although the typical ulcer involves only the mucosa, deeper degrees of penetration can occur, and localized perforation has been reported [<a href="#rid17">17,18</a>]. Remnants of the offending pill may occasionally be identified at the site of injury. Esophageal strictures may be noted on upper endoscopy, especially in patients with nonsteroidal anti-inflammatory drug (NSAID)-, quinidine-, and potassium chloride-induced esophagitis [<a href="#rid19">19</a>]. The sensitivity of upper endoscopy for pill esophagitis approaches 100 percent, but the endoscopic findings of pill esophagitis are not specific [<a href="#rid1">1</a>].</p><p>Histologic features of pill esophagitis are also nonspecific and include eosinophilic microabscesses, intraepithelial pustules, and a diffuse pattern of dilated intercellular spaces, which, along with its predilection for involving the mid as opposed to the distal esophagus, can differentiate it from reflux esophagitis  (<a class="graphic graphic_diagnosticimage graphicRef134868" href="/z/d/graphic/134868.html" rel="external">image 2</a>) [<a href="#rid20">20</a>]. The inflammatory infiltrate seen in pill esophagitis is usually dominated by T cells, followed by eosinophils.</p><p class="headingAnchor" id="H105736636"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis of pill esophagitis includes other causes of esophagitis, retrosternal pain, and/or dysphagia and can be distinguished from them by upper endoscopy and biopsy  (<a class="graphic graphic_table graphicRef80528" href="/z/d/graphic/80528.html" rel="external">table 2</a>). The evaluation of patients with dysphagia is also discussed in detail, separately. (See  <a class="medical medical_review" href="/z/d/html/2241.html" rel="external">"Approach to the evaluation of dysphagia in adults", section on 'Symptom-based differential diagnosis'</a>.)</p><p class="headingAnchor" id="H174813382"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H4153156462"><span class="h2">General measures</span></p><p class="headingAnchor" id="H737211517"><span class="h3">Discontinuation of offending medication</span><span class="headingEndMark"> — </span>The initial step in management is to discontinue the offending medication. Most cases of medication-induced esophageal injury heal without intervention within a few days of discontinuing the culprit medication [<a href="#rid14">14</a>]. In the vast majority of cases and in those uncomplicated by stricture, symptoms usually resolve within 7 to 10 days, but in some patients symptoms persist for many weeks after the culprit medication has been discontinued. Patients with persistent symptoms one week after discontinuation of the culprit medication require additional evaluation with upper endoscopy if not already performed to establish the diagnosis. (See <a class="local">'Upper endoscopy and biopsy in selected patients'</a> above.)</p><p class="headingAnchor" id="H2588563789"><span class="h3">Acid suppression</span><span class="headingEndMark"> — </span>We use standard-dose proton pump inhibitors until symptoms have resolved as gastroesophageal reflux disease may be exacerbating or perpetuating the pill-induced injury. Although the use of other acid suppressive medication (eg, antacids, histamine receptor antagonists) and surface agents (eg, <a class="drug drug_general" data-topicid="9953" href="/z/d/drug information/9953.html" rel="external">sucralfate</a>, and local anesthetic agents) are all commonly advised, it is unclear if they are effective in treating pill esophagitis. (See  <a class="medical medical_review" href="/z/d/html/2258.html" rel="external">"Medical management of gastroesophageal reflux disease in adults", section on 'Severe or frequent symptoms or erosive esophagitis'</a>.)</p><p class="headingAnchor" id="H3327917623"><span class="h3">Supportive care</span><span class="headingEndMark"> — </span>Patients with severe odynophagia who are unable to eat or drink may require short-term parenteral hydration or alimentation. (See <a class="local">'Clinical manifestations'</a> above.)</p><p class="headingAnchor" id="H3489958052"><span class="h2">Prevention of recurrence</span></p><p class="headingAnchor" id="H2931142216"><span class="h3">Medication resumption</span><span class="headingEndMark"> — </span>In patients without an apparent predisposition to esophageal injury (eg, a large left atrium), the culprit medication may be resumed after symptoms resolve. Pills implicated in causing frequent or severe pill esophagitis should be avoided in bed-ridden patients or those with esophageal motility disorders. In patients predisposed to recurrent injury who need to continue the culprit medication, a liquid formulation should be prescribed if possible. (See <a class="local">'Etiology'</a> above and <a class="local">'Precautions to decrease risk'</a> below.)</p><p class="headingAnchor" id="H1709843356"><span class="h3">Addressing predisposing factors</span><span class="headingEndMark"> — </span>To minimize the risk of recurrence, the underlying predisposing factors should be addressed. This may require additional evaluation (eg, air contrast <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">barium</a> study in patients in whom extrinsic esophageal compression is suspected or esophageal manometry evaluation for an underlying motility disorder) or treatment (eg, endoscopic dilation in patients with an esophageal stricture or optimizing management of gastroesophageal reflux). (See  <a class="medical medical_review" href="/z/d/html/2241.html" rel="external">"Approach to the evaluation of dysphagia in adults", section on 'Approach to diagnostic testing'</a> and  <a class="medical medical_review" href="/z/d/html/2270.html" rel="external">"Endoscopic interventions for nonmalignant esophageal strictures in adults", section on 'Endoscopic dilation'</a>.)</p><p class="headingAnchor" id="H174813416"><span class="h3">Precautions to decrease risk</span><span class="headingEndMark"> — </span>We suggest the following measures to minimize the risk of medication-induced esophagitis:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients should take all pills in an upright posture.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients should drink at least 4 ounces of fluid with any medication and 8 ounces with medications that are strongly associated with pill esophagitis (eg, <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a>, <a class="drug drug_general" data-topicid="9427" href="/z/d/drug information/9427.html" rel="external">alendronate</a>, <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">potassium chloride</a>, or <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">quinidine</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients should remain upright for at least 10 minutes after taking any pills and for at least 30 minutes with pills that are strongly associated with pill esophagitis.</p><p></p><p class="headingAnchor" id="H110689707"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/138520.html" rel="external">"Patient education: Esophagitis (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/15732.html" rel="external">"Patient education: Upper endoscopy (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/1992.html" rel="external">"Patient education: Upper endoscopy (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H160410701"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology</strong> – Medications can cause direct esophageal mucosal injury, commonly referred to as pill esophagitis. More than 100 different medications and supplements have been reported to cause pill esophagitis  (<a class="graphic graphic_table graphicRef135178" href="/z/d/graphic/135178.html" rel="external">table 1</a>). (See <a class="local">'Etiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – Pill esophagitis is likely caused by prolonged contact of the medication with the esophageal mucosa owing to delayed esophageal transit. The size of the medication, position of the patient, and amount of fluid ingested with the medication all affect the rate of esophageal transit. (See <a class="local">'Risk factors'</a> above and <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptoms</strong> – Patients with pill esophagitis often present with the sudden onset of odynophagia, dysphagia, or retrosternal pain. The onset of the symptoms usually occurs within a few hours to three days after ingestion of the drug. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Pill esophagitis should be suspected in patients with retrosternal pain or odynophagia and a history of ingestion of medications known to cause pill esophagitis. In these cases, a clinical diagnosis may be made by history alone. We perform an upper endoscopy with biopsy in patients with severe symptoms, atypical symptoms (hematemesis, abdominal pain, and weight loss), or persistent symptoms one week after discontinuation of culprit medications. In such cases, an upper endoscopy with biopsy serves to establish the diagnosis and to rule out other etiologies  (<a class="graphic graphic_diagnosticimage graphicRef134866" href="/z/d/graphic/134866.html" rel="external">image 1</a> and <a class="graphic graphic_diagnosticimage graphicRef134868" href="/z/d/graphic/134868.html" rel="external">image 2</a>). (See <a class="local">'Diagnostic evaluation'</a> above and <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>General measures</strong> – The initial step in management is to discontinue the offending medication. Most cases of medication-induced esophageal injury heal without intervention within a few days of discontinuing the culprit medication. We use acid suppression with a standard-dose proton pump inhibitor until symptoms have resolved as gastroesophageal reflux may be exacerbating or perpetuating the pill-induced injury.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prevention of recurrence</strong> – In patients without an apparent predisposition to esophageal injury, the culprit medication may be resumed after symptoms resolve, with careful instructions on how to take the medication. In patients predisposed to recurrent injury who need to continue the culprit medication, a liquid formulation should be prescribed if possible. (See <a class="local">'Management'</a> above and <a class="local">'Precautions to decrease risk'</a> above.)</p><p></p><p class="headingAnchor" id="H5796186"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Donald O Castell, MD, now deceased, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kikendall JW. Pill esophagitis. J Clin Gastroenterol 1999; 28:298.</a></li><li><a class="nounderline abstract_t">Hughes R. Drug-induced oesophageal injury. Br Med J 1979; 2:132.</a></li><li><a class="nounderline abstract_t">Kim SH, Jeong JB, Kim JW, et al. Clinical and endoscopic characteristics of drug-induced esophagitis. World J Gastroenterol 2014; 20:10994.</a></li><li><a class="nounderline abstract_t">Hey H, Jørgensen F, Sørensen K, et al. Oesophageal transit of six commonly used tablets and capsules. Br Med J (Clin Res Ed) 1982; 285:1717.</a></li><li><a class="nounderline abstract_t">Pouderoux P, Shi G, Tatum RP, Kahrilas PJ. Esophageal solid bolus transit: studies using concurrent videofluoroscopy and manometry. Am J Gastroenterol 1999; 94:1457.</a></li><li><a class="nounderline abstract_t">Zografos GN, Georgiadou D, Thomas D, et al. Drug-induced esophagitis. Dis Esophagus 2009; 22:633.</a></li><li><a class="nounderline abstract_t">Miyata J, Ito Y, Ito S. Pill-induced esophagitis caused by ingesting excessive caffeine tablets. Clin J Gastroenterol 2020; 13:334.</a></li><li><a class="nounderline abstract_t">O'Donnell C, Tandon P, Govardhanam V, Habal F. Pill-Induced Esophagitis From Intake of Dietary Supplements. ACG Case Rep J 2019; 6:e00106.</a></li><li><a class="nounderline abstract_t">Zimmer V, Emrich K. Azithromycin-Induced Pill Esophagitis. GE Port J Gastroenterol 2021; 28:225.</a></li><li><a class="nounderline abstract_t">Fazil M, Baboota S, Sahni JK, et al. Bisphosphonates: therapeutics potential and recent advances in drug delivery. Drug Deliv 2015; 22:1.</a></li><li><a class="nounderline abstract_t">Dent J, Dodds WJ, Friedman RH, et al. Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects. J Clin Invest 1980; 65:256.</a></li><li><a class="nounderline abstract_t">Carlborg B, Densert O, Lindqvist C. Tetracycline induced esophageal ulcers. a clinical and experimental study. Laryngoscope 1983; 93:184.</a></li><li><a class="nounderline abstract_t">Olovson SG, Björkman JA, Ek L, Havu N. The ulcerogenic effect on the oesophagus of three beta-adrenoceptor antagonists, investigated in a new porcine oesophagus test model. Acta Pharmacol Toxicol (Copenh) 1983; 53:385.</a></li><li><a class="nounderline abstract_t">Abid S, Mumtaz K, Jafri W, et al. Pill-induced esophageal injury: endoscopic features and clinical outcomes. Endoscopy 2005; 37:740.</a></li><li><a class="nounderline abstract_t">Parfitt JR, Jayakumar S, Driman DK. Mycophenolate mofetil-related gastrointestinal mucosal injury: variable injury patterns, including graft-versus-host disease-like changes. Am J Surg Pathol 2008; 32:1367.</a></li><li><a class="nounderline abstract_t">Jaspersen D. Drug-induced oesophageal disorders: pathogenesis, incidence, prevention and management. Drug Saf 2000; 22:237.</a></li><li><a class="nounderline abstract_t">Henry JG, Shinner JJ, Martino JH, Cimino LE. Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride. Pediatr Cardiol 1983; 4:251.</a></li><li><a class="nounderline abstract_t">Singh NP, Rizk JG. Oesophageal perforation following ingestion of over-the-counter ibuprofen capsules. J Laryngol Otol 2008; 122:864.</a></li><li><a class="nounderline abstract_t">Bonavina L, DeMeester TR, McChesney L, et al. Drug-induced esophageal strictures. Ann Surg 1987; 206:173.</a></li><li><a class="nounderline abstract_t">Kim JW, Kim BG, Kim SH, et al. Histomorphological and Immunophenotypic Features of Pill-Induced Esophagitis. PLoS One 2015; 10:e0128110.</a></li></ol></div><div id="topicVersionRevision">Topic 2255 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10372925" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pill esophagitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/466311" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Drug-induced oesophageal injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25152603" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical and endoscopic characteristics of drug-induced esophagitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6816343" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Oesophageal transit of six commonly used tablets and capsules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10364007" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Esophageal solid bolus transit: studies using concurrent videofluoroscopy and manometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19392845" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Drug-induced esophagitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31646430" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pill-induced esophagitis caused by ingesting excessive caffeine tablets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31616773" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pill-Induced Esophagitis From Intake of Dietary Supplements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34056050" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Azithromycin-Induced Pill Esophagitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24404750" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Bisphosphonates: therapeutics potential and recent advances in drug delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7356677" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6823189" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Tetracycline induced esophageal ulcers. a clinical and experimental study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6140813" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The ulcerogenic effect on the oesophagus of three beta-adrenoceptor antagonists, investigated in a new porcine oesophagus test model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16032493" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pill-induced esophageal injury: endoscopic features and clinical outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18763324" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Mycophenolate mofetil-related gastrointestinal mucosal injury: variable injury patterns, including graft-versus-host disease-like changes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10738847" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Drug-induced oesophageal disorders: pathogenesis, incidence, prevention and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6647113" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18452637" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Oesophageal perforation following ingestion of over-the-counter ibuprofen capsules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3606243" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Drug-induced esophageal strictures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26047496" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Histomorphological and Immunophenotypic Features of Pill-Induced Esophagitis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
